{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T10:13:37Z","timestamp":1770977617564,"version":"3.50.1"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> To explore the attitudes and views of patients with inflammatory bowel disease (IBD) on COVID-19 vaccination.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> An online interview questionnaire concerning the acceptance or hesitancy toward vaccination for COVID-19 was designed and 543 patients with IBD in China were invited to complete the structured self-administered anonymous questionnaire.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Of all the participants, 50.7% were indecisive about the vaccination and only 16.0% opted for it. Vaccination hesitancy was significantly associated with women and those without medical or biomedical backgrounds. The acceptance of COVID-19 vaccination was higher in participants with no history of immune-modifying therapies, especially in those without immunosuppressants. Participants who considered vaccination critically important to self-health or the health of others were more likely to choose immediately or later vaccination. Safety and potential adverse reactions, personal hypoimmunity, efficacy, and reliability of COVID-19 vaccines were the top three concerns of the participants that were independent of their willingness for vaccination.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This study discloses the presence of hesitancy for COVID-19 vaccination in patients with IBD. Further studies are warranted to evaluate the efficacy and safety of COVID-19 vaccines in IBD individuals, with a specific focus on the impact of immune-modifying therapies. Health education and recommendation from authoritative sources may facilitate COVID-19 vaccination efforts.<\/jats:p>","DOI":"10.3389\/fpubh.2021.731578","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T04:22:06Z","timestamp":1634012526000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Xia","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heena","family":"Buch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quchen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bota","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guozhong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"B1","unstructured":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/apt.15804","article-title":"2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases","volume":"52","author":"Taxonera","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/ecco-jcc\/jjaa126","article-title":"Inflammatory bowel disease in the COVID-19 pandemic - the patients' perspective","volume":"14","author":"Grunert","year":"2020","journal-title":"J Crohns Colitis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/s2468-1253(20)30151-5","article-title":"Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey","volume":"5","author":"D'Amico","year":"2020","journal-title":"Lancet Gastroenterol Hepato."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1053\/j.gastro.2020.04.002","article-title":"International organization for the study of inflammatory bowel D. Management of patients with crohn's disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology."},{"key":"B6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"Ungaro","year":"2021","journal-title":"Gut."},{"key":"B7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2020.05.032","article-title":"Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry","volume":"159","author":"Brenner","year":"2020","journal-title":"Gastroenterology."},{"key":"B8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1053\/j.gastro.2020.04.012","article-title":"Clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary","volume":"159","author":"Rubin","year":"2020","journal-title":"Gastroenterology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41575-020-0294-8","article-title":"Management of IBD during the COVID-19 outbreak: resetting clinical priorities","volume":"17","author":"Danese","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/gutjnl-2020-323020","article-title":"Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19","volume":"70","author":"Yeoh","year":"2021","journal-title":"Gut."},{"key":"B11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1111\/codi.15138","article-title":"Persistent viral shedding of SARS-CoV-2 in faeces - a rapid review","volume":"22","author":"Gupta","year":"2020","journal-title":"Colorectal Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/s0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S2468-1253(20)30295-8","article-title":"COVID-19 vaccinations in patients with inflammatory bowel disease","volume":"5","author":"Kumar","year":"2020","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.crohns.2012.05.011","article-title":"Immune response to influenza A\/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-alpha agents: effects of combined therapy with immunosuppressants","volume":"7","author":"Andrisani","year":"2013","journal-title":"J Crohns Colitis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ibd.21706","article-title":"Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease","volume":"18","author":"deBruyn","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ibd.21800","article-title":"Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study","volume":"18","author":"Fiorino","year":"2012","journal-title":"Inflamm Bowel Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/gutjnl-2020-324000","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting","volume":"70","author":"Siegel","year":"2021","journal-title":"Gut."},{"key":"B20","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(21)00024-8","article-title":"SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement","volume":"6","author":"Alexander","year":"2021","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"m4838","DOI":"10.1136\/bmj.m4838","article-title":"Covid-19 vaccines: delivering protective immunity","volume":"371","author":"Sewell","year":"2020","journal-title":"BMJ."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1016\/j.vaccine.2021.04.020","article-title":"Vaccination willingness, vaccine hesitancy, and estimated coverage at the first round of COVID-19 vaccination in China: A national cross-sectional study","volume":"39","author":"Wang","year":"2021","journal-title":"Vaccine."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1016\/j.cgh.2021.02.004","article-title":"COVID-19 Vaccination intent and perceptions among patients with inflammatory bowel diseases","volume":"19","author":"Dalal","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab172","article-title":"COVID-19 vaccination willingness and hesitancy in patients with inflammatory bowel diseases: analysis of determinants in a national survey of the Italian IBD patients' association","author":"Costantino","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.2147\/PPA.S265346","article-title":"Insufficient knowledge and vaccination practice of inflammatory bowel disease patients in the People's Republic of China","volume":"14","author":"Feng","year":"2020","journal-title":"Patient Prefer Adherence."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-2667(21)00012-8","article-title":"COVID-19 vaccine hesitancy in a representative working-age population in France: a survey experiment based on vaccine characteristics","author":"Schwarzinger","year":"2021","journal-title":"The Lancet Public Health."},{"key":"B27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3390\/vaccines8030482","article-title":"Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in China","volume":"8","author":"Wang","year":"2020","journal-title":"Vaccines (Basel)."},{"key":"B28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/ibd\/izaa055","article-title":"Optimizing immunization strategies in patients with IBD","volume":"27","author":"Caldera","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"9775","DOI":"10.3390\/ijms21249775","article-title":"The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic","volume":"21","author":"Won","year":"2020","journal-title":"Int J Mol Sci."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.731578\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T04:22:09Z","timestamp":1634012529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2021.731578\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":30,"alternative-id":["10.3389\/fpubh.2021.731578"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2021.731578","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,11]]},"article-number":"731578"}}